Akouos
Brookline, US · Founded 2017 · Delaware corporation · 45 employees on LinkedIn · 8 known investors
Akouos is a precision genetic medicine company developing therapies for the inner ear to restore, improve, and preserve hearing. It focuses on treating the underlying causes of hearing loss, including genetic hearing loss.
Founders & leadership
Akouos was founded in 2017 by Emmanuel Simons and william sewell.
ES
Emmanuel SimonsCo-founder
WS
william sewellinFounder
Board
EM
KP
Investors · 8
5AM VenturesBoston · $100K – $4Mvia Arthur Tzianabos · board
EcoR1 CapitalSan Francisco
New Enterprise Associates (NEA)Menlo Park · $200K – $40Mvia Ed Mathers · board
RA CapitalBoston
Sofinnova VenturesMenlo Park · $100K – $15M
Cowen Healthcare InvestmentsreportedNew York
Fidelity InvestmentsreportedBoston
Pivotal Life SciencesreportedSan Francisco
Reported raises · per SEC filings
Form D private placements$137.7M disclosed across 3 rounds · 2017–2020
▶$105.1MraisedMar 2020 · 33 investors · BiotechnologyRule 506(b)
▶$105.1MraisedMar 2020 · 33 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Ed MathersDirector
- Kush ParmarDirector
- Karoline ShairExecutive Officer
- Chris SmithDirector
- Heather PrestonDirector
- Vicki SatoDirector
- Aninda KatragaddaExecutive Officer
- Emmanuel SimonsExecutive Officer, Director
- Arthur TzianabosDirector
- Offering amount
- $105.1M
- Amount sold
- $105.1M
- First sale
- Feb 2020
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
▶$25.1MraisedAug 2018 · 10 investors · BiotechnologyRule 506(b)
▶$25.1MraisedAug 2018 · 10 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Chris SmithDirector
- Emmanuel SimonsExecutive Officer, Director
- Arthur TzianabosDirector
- Ed MathersDirector
- Kush ParmarDirector
- Offering amount
- $50.1M
- Amount sold
- $25.1M
- First sale
- Jul 2018
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$7.6MraisedNov 2017 · 8 investors · BiotechnologyRule 506(b)
▶$7.6MraisedNov 2017 · 8 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Emmanuel SimonsExecutive Officer, Director
- Ed MathersDirector
- Kush ParmarDirector
- Offering amount
- $7.6M
- Amount sold
- $7.6M
- First sale
- Oct 2017
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 1
by search overlapCompanies competing with Akouos for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Akouos do?
- Akouos is a precision genetic medicine company developing therapies for the inner ear to restore, improve, and preserve hearing. It focuses on treating the underlying causes of hearing loss, including genetic hearing loss.
- Who founded Akouos?
- Akouos was founded by Emmanuel Simons, william sewell in 2017.
- Who are Akouos's investors?
- Akouos's investors include 5AM Ventures, EcoR1 Capital, New Enterprise Associates (NEA), RA Capital, Sofinnova Ventures, Cowen Healthcare Investments, Fidelity Investments, Pivotal Life Sciences.
- How much funding has Akouos raised?
- Akouos has disclosed $137.7M raised across 3 rounds.
- Where is Akouos headquartered?
- Akouos is headquartered in Brookline, US.